QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

3 evidence topics · 2 sources

Manufacturer: Palvella Therapeutics

Field	Quoted record
Sponsor	“Palvella Therapeutics, Inc.”

Product name

“QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin)” (opens the source at this quote in a new tab)

Generic name

“sirolimus” (opens the source at this quote in a new tab)